Carlsmed (CARL) EBITDA (2024 - 2026)

Carlsmed (CARL) has 3 years of EBITDA data on file, last reported at -$8.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 51.79% year-over-year to -$8.7 million; the trailing twelve-month figure through Mar 2026 stood at -$32.6 million (down 32.85% YoY), and the FY2025 full-year result was -$29.6 million, down 22.17% from the prior year.
• EBITDA for Q1 2026 stood at -$8.7 million, down from -$8.6 million in the prior quarter.
• Across five years, EBITDA topped out at -$4.7 million in Q4 2024 and bottomed at -$8.7 million in Q1 2026.
• The 3-year median for EBITDA is -$7.3 million (2024), against an average of -$7.1 million.
• Peak annual rise in EBITDA reached 7.79% in 2025, while the deepest fall reached 82.48% in 2025.
• A 3-year view of EBITDA shows it stood at -$4.7 million in 2024, then plunged by 82.48% to -$8.6 million in 2025, then declined by 0.96% to -$8.7 million in 2026.
• The last three EBITDA figures came in at -$8.7 million (Q1 2026), -$8.6 million (Q4 2025), and -$8.5 million (Q3 2025), per Business Quant data.

Peer Comparison